|
Synonyms: anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736
durvalumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [2], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [1]. |
Classification  |
|
| Compound class | Antibody |
| Ligand families/groups | Immune checkpoint modulators |
| Approved drug? | Yes (FDA (2017), EMA (2018)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10010 | durvalumab |
| Synonyms |
| anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 528 |
| Other databases | |
| GtoPdb PubChem SID | 249565666 |
| Search PubMed clinical trials | durvalumab |
| Search PubMed titles | durvalumab |
| Search PubMed titles/abstracts | durvalumab |
| Wikipedia | Durvalumab |
